Could fewer chemo cycles be just as effective for some lymphoma patients?
NCT ID NCT05018520
First seen May 12, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This study compares two treatment schedules for people with a common type of lymphoma (DLBCL) that is low-risk and hasn't spread. Participants will receive either 4 cycles of R-CHOP followed by 4 doses of rituximab, or 6 cycles of R-CHOP followed by 2 doses of rituximab. The goal is to see if the shorter chemo course is as safe and effective at preventing the cancer from coming back within two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
RECRUITINGShanghai, Shanghai Municipality, 200020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.